Cooperative Agreement 2335297
Award Date
9/1/24
Completion Date
8/31/26
Dollars Obligated
$999K
Federal Agency
National Science Foundation
Federal Grant Program
47.084
Assistance Type
Cooperative Agreement
Place of Performance
Princeton, NJ 08544, USA
Similar Awards
Cryptyx Bioscience, Inc. was awarded a $256,000 Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program (NSF TIP, CFDA 47.084) to develop a novel small-molecule drug discovery platform based on high-throughput elicitor screening. The platform will trigger the production of cryptic microbial metabolites for evaluation as potential new pharmaceuticals to address a range of diseases. During the one-year period from April 1, 2022 to March 31, 2023, the...
This Project Grant award of $275,000 from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) supports the development of a novel platform for massive, empirical, and scalable generation of small molecule and protein interaction data. The goal is to enable more efficient discovery of new medicines using machine learning. The key products and services to be delivered under this SBIR Phase I award include: Demonstrating the ability to identify...
This SBIR Phase I award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $273,550 to Biocognon LLC for the development of a combinatorial platform to discover improved molecular recognition components for use in therapeutic and diagnostic antibodies. The project aims to utilize synthetic biology, next-generation DNA sequencing, and computational biology to efficiently generate and screen libraries of antibody...
This $274,990 Small Business Innovation Research (SBIR) Phase I award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships) supports the development of a physics-based machine learning platform for predicting the crystal structure of small drug molecules. The technology aims to accelerate and reduce the cost of early-stage pharmaceutical research and development by computationally analyzing the crystal structure properties that determine key...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 provides funding to Clue Genetics Inc. for the development of a fungi-focused metabologenomics platform for natural product discovery. The key products and services to be delivered under this 1-year Phase I SBIR project include: Annotating biosynthetic gene clusters (BGCs) from 200 genomes selected from a diverse set of bioactive fungi to uncover new drugs,...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $303,864 to Core Biotherapeutics Inc. aims to develop a platform for disruptive drug candidates that can reprogram molecular networks to produce therapeutic effects beyond single-target approaches. The key objectives are to: 1) demonstrate that oligonucleotide drug efficacy is a function of transcription factor (TF) network reprogramming using a breast cancer cell line, 2) build a...
This $305,000 Small Business Innovation Research (SBIR) Phase I project awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) aims to develop a new class of gene therapies delivered more safely, cost-effectively, and at scale for serious genetic disorders. The project leverages short oligonucleotides conjugated with small molecules to induce proximity of endogenous epigenetic machinery to disease-relevant genes,...
This Project Grant award of $303,445 from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) supports the development of a next-generation sequencing platform for discovering small molecules that target RNA. The project aims to address the challenge of identifying RNA-binding small molecules capable of modulating protein expression, which could enable therapeutic interventions for diseases currently lacking treatment options, such as...
This Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $275,000 to Foragr Medicines, Inc. to develop a high-throughput platform for small molecule targeting of undruggable proteins via their mRNAs. The platform aims to enable an efficient and cost-effective approach for developing therapeutics for previously undruggable diseases, including neurodegenerative diseases and aggressive cancers. The project will...
This National Science Foundation (NSF) SBIR Phase I Project Grant under the Technology, Innovation, and Partnerships (CFDA 47.084) program provides $274,990 in funding to Eascra Biotech, Inc., a small business based in Pawtucket, Rhode Island. The project aims to advance the regulatory pathway for commercializing space-made Janus Base Nanoparticles (JBNPs) as an innovative drug delivery system for treating solid tumors. Phase I will demonstrate the comparability of space-manufactured JBNPs to...